SOURCE: MicroMed Cardiovascular, Inc.

May 22, 2007 15:36 ET

MicroMed Announces First Implant of the DeBakey VAD® X2 Design in the United Kingdom

HOUSTON, TX -- (MARKET WIRE) -- May 22, 2007 -- MicroMed Cardiovascular, Inc. (OTCBB: MMCV) is pleased to announce that on Monday, May 14, 2007, doctors at Freeman Hospital in Newcastle upon Tyne, England, United Kingdom(UK), successfully implanted the latest design DeBakey VAD® "X2" pump in a 59-year-old man.

"I'm proud to say that yesterday we implanted a MicroMed Cardiovascular, Inc. DeBakey ventricular assist device in a patient with severe ischemic cardiomyopathy and he's doing very well. Less than 24 hours after the surgery the patient is awake and alert and is quite happy with the results," said the implanting surgeon, Mr. Stephen C. Clark.

This implant marks the initial implant for the UK market of the latest X2 design of the MicroMed DeBakey VAD®. The product provides an excellent therapy option for patients who are too sick to survive until a donor heart can be found.

About MicroMed Cardiovascular, Inc.

The DeBakey VAD® is a very small ventricular assist device (VAD) which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is an implantable axial flow device designed to provide long term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians' patient care. It is CE-Mark approved in Europe for Bridge-to-Transplant (BTT), Destination Therapy (DT), and pediatric use with the DeBakey VAD® Child. The DeBakey VAD® is undergoing an IDE BTT clinical study in the U.S. and the DeBakey VAD® Child is the only FDA approved (HDE) pediatric ventricular assist device. MicroMed Cardiovascular, Inc. trades on the over the counter bulletin board under the trading symbol MMCV.

Forward-looking statements in this release regarding MicroMed Cardiovascular, Inc. are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition, new products and technological changes, the company's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact
    Allison K. Wehner
    Marketing and Corporate Communications Coordinator
    Phone: (713) 580-8270
    Fax: (713) 838-9214
    Email Contact